Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
Gouriou C, Lemanski C, Pommier P, Le Malicot K, Saint A, Rivin Del Campo E, Evin C, Quero L, Regnault P, Baba-Hamed N, Ronchin P, Crehange G, Tougeron D, Menager-Tabourel E, Diaz O, Hummelsberger M, de la Rocherfordiere A, Drouet F, Vendrely V, Lièvre A. Gouriou C, et al. Among authors: ronchin p. Br J Cancer. 2024 Mar;130(5):769-776. doi: 10.1038/s41416-023-02564-9. Br J Cancer. 2024. PMID: 38184691
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V. Giraud N, et al. Among authors: ronchin p. Cancers (Basel). 2021 Jan 7;13(2):193. doi: 10.3390/cancers13020193. Cancers (Basel). 2021. PMID: 33430396 Free PMC article.
What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.
Bacci M, Quero L, Barbier E, Parrot L, Juguet F, Pommier P, Bazire L, Etienney I, Baba-Hamed N, Spindler L, François E, Ronchin P, Campo ERD, Lemanski C, Lièvre A, Siproudhis L, Abramowitz L, Lepage C, Vendrely V. Bacci M, et al. Among authors: ronchin p. Dig Liver Dis. 2021 Jun;53(6):776-784. doi: 10.1016/j.dld.2021.03.015. Epub 2021 Apr 16. Dig Liver Dis. 2021. PMID: 33867291
Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.
François E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, Clavere P, Vendrely V, Boige V, Gargot D, Lemanski C, De Sousa Carvalho N, Gal J, Pernot M, Magné N. François E, et al. Among authors: ronchin p. Eur J Cancer. 2023 Feb;180:62-70. doi: 10.1016/j.ejca.2022.11.020. Epub 2022 Nov 28. Eur J Cancer. 2023. PMID: 36535196 Clinical Trial.
Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
Vendrely V, Lemanski C, Pommier P, LE Malicot K, Saint A, Rivin Del Campo E, Regnault P, Baba-Hamed N, Ronchin P, Crehange G, Tougeron D, Menager-Tabourel E, Diaz O, Hummelsberger M, Minsat M, Drouet F, Larrouy A, Peiffert D, Lievre A, Zasadny X, Hautefeuille V, Mornex F, Lepage C, Quero L; for FFCD investigators/collaborators. Vendrely V, et al. Among authors: ronchin p. Radiother Oncol. 2023 Jun;183:109542. doi: 10.1016/j.radonc.2023.109542. Epub 2023 Feb 21. Radiother Oncol. 2023. PMID: 36813175 Free article.
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A, Rio E, Bera G, Ruffier A, Quivrin M, Chasseray M, Latorzeff I, Martin E, Guimas V, Pommier P, Leroy T, Ronchin P, Lepinoy A, Grand A, Cartier L, Didas O, Denis F, Libois V, Blanc-Lapierre A, Supiot S. Rogé M, et al. Among authors: ronchin p. Clin Transl Radiat Oncol. 2023 Mar 8;40:100613. doi: 10.1016/j.ctro.2023.100613. eCollection 2023 May. Clin Transl Radiat Oncol. 2023. PMID: 36968576 Free PMC article.
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Vendrely V, Ronchin P, Minsat M, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Darut-Jouve A, de la Fouchardière C, Giraud N, Breysacher G, Argo-Leignel D, Thimonnier E, Magné N, Abdelghani MB, Lepage C, Aparicio T; for FFCD investigators/Collaborators. Vendrely V, et al. Among authors: ronchin p. Radiother Oncol. 2023 Sep;186:109742. doi: 10.1016/j.radonc.2023.109742. Epub 2023 Jun 12. Radiother Oncol. 2023. PMID: 37315583 Free article. Clinical Trial.
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
Modesto A, Tougeron D, Tremolières P, Ronchin P, Jouve AD, Leignel DA, Vendrely V, Riou O, Martin-Babau J, Le Sourd S, Mirabel X, Leroy T, Huguet F, Montaigne L, Baumgaertner I, Deslandres M, Moyal E, Seva C, Selves J, Otal P, Pezzella V, Guimbaud R, Filleron T, Quéro L. Modesto A, et al. Among authors: ronchin p. BMC Cancer. 2023 Oct 12;23(1):966. doi: 10.1186/s12885-023-11227-0. BMC Cancer. 2023. PMID: 37828434 Free PMC article.
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment.
François E, Magné N, Boulahssass R, Ronchin P, Huguenet V, De Lavigerie B, Nouhaud E, Cattenoz C, Martel-Lafay I, Terret C, Artru P, Clavere P, Tchalla A, Vendrely V, Duc S, Boige V, De Sousa Carvalho N, Gal J, De Bari B. François E, et al. Among authors: ronchin p. Radiother Oncol. 2024 Apr;193:110144. doi: 10.1016/j.radonc.2024.110144. Epub 2024 Feb 8. Radiother Oncol. 2024. PMID: 38341097
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Conroy T, et al. Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13. Lancet Oncol. 2021. PMID: 33862000 Clinical Trial.
21 results